It’s abundantly clear that all the key clinical programs are...

It’s abundantly clear that all the key clinical programs are progressing exceptionally well and corporately the board has ensured the balance sheet is robust to weather the current economic environment. Aussie $37.1M of cash, and operating within your highly efficient R&D jurisdiction.

OSA looks to be a company maker, however I’m increasingly of the view that IHL-675A might be an even greater market opportunity.

This is a sensational update and IMO any short term thinking will dissipate in better market conditions. Negatively is just human nature and while I understand this attitude it’s also irrelevant if you have a well researched view of the fundamentals and management. My greatest disappointment is not being able to capitalise on the options as I’m based in the US.